A pivotal Phase 3 trial of RX-3117

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 08 Dec 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

29 Nov 2023 According to Processa Pharmaceuticals media release, discussion with the FDA to determine Phase 2b/3a study design expected in the first half of 2024
28 Jun 2021 New trial record
17 Jun 2021 According to a Processa Pharmaceuticals media release, company expect to obtain biomarker data from phase 2b trial, that will identify patients who will benefit the most from this drug while significantly increasing the probability of a successful Phase 3 trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com